First-in-class therapeutic mechanism for Diastolic Heart Failure treatment
Heart failure is the leading cause of hospitalization for those >65 years and the mortality is >50% within 5 years after first hospital admission. These patients' expenses amount to 2–3% of the total United States healthcare spending. The total US market for heart failure treatments is worth >40 bln USD. Vasa Therapeutics is striving to discover novel heart failure medicines using mechanisms that directly improve heart function and employing precision medicine-based patient stratification.
The target patients for Vasa 1 program are Heart Failure with Preserved Ejection Fraction (HFpEF) patients after first hospitalization for which there currrently is no standard of care. The program looks into MMPs, which are biomarkers and targets of HFpEF. Vasa has developed a proprietary scaffold identified internally and filled a composition of matter filling in Q4 2021.